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Abstract
Background: Somatic mutations in the mitochondrial genome occur in numerous tumor types
including brain tumors. These mutations are generally found in the hypervariable regions I and II of
the displacement loop and unlikely alter mitochondrial function. Two hypervariable regions of
mononucleotide repeats occur in the mouse mitochondrial genome, i.e., the origin of replication
of the light strand (OL) and the Arg tRNA.
Methods: In this study we examined the entire mitochondrial genome in a series of chemically
induced brain tumors in the C57BL/6J strain and spontaneous brain tumors in the VM mouse strain.
The tumor mtDNA was compared to that of mtDNA in brain mitochondrial populations from the
corresponding syngeneic mouse host strain.
Results:  Direct sequencing revealed a few homoplasmic base pair insertions, deletions, and
substitutions in the tumor cells mainly in regions of mononucleotide repeats. A heteroplasmic
mutation in the 16srRNA gene was detected in a spontaneous metastatic VM brain tumor.
Conclusion: None of the mutations were considered pathogenic, indicating that mtDNA somatic
mutations do not likely contribute to the initiation or progression of these diverse mouse brain
tumors.
Background
Mitochondrial DNA (mtDNA) is essential for the produc-
tion of subunits for the electron transport chain, since it
encodes peptides for Complex I, III, IV, and V. The mito-
chondrial genome consists of a 16.5 kb piece of circular
DNA encoding 37 genes on the L and H strands. These
include 22 tRNAs, 2 rRNAs, and 13 respiratory chain sub-
units [1]. The mitochondrial genetic code varies slightly
from the nuclear genetic code and the mutation rate of the
mitochondrial genome is 10 fold higher than that of the
nuclear genome [2-4]. This higher mutation rate may be
due in part to a lack of protective histones, reduced fidelity
of polymerase γ, or to the localization of the mitochon-
drial genome to the inner mitochondrial membrane near
damaging reactive oxygen species [5-9]. mtDNA muta-
tions may also contribute to a decrease in metabolic effi-
ciency that enhances aging, promotes neurodegeneration,
and is conducive to carcinogenesis [10-12].
mtDNA mutations have been studied in various types of
cancers, including breast [13], bladder, lung, head and
neck [14], gastric [15], esophageal [16], pancreatic [17],
and colon [18]. The majority of the mutations in the mito-
chondrial genome of human tumors were found in the
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hypervariable regions of the displacement loop (D-loop)
[19-21]. Alterations in these hypervariable regions are
unlikely to alter mitochondrial function or produce a dis-
eased phenotype [22]. These hypervariable regions corre-
spond to the OL and Arg tRNA in mouse mtDNA [23].
Otto Warburg originally emphasized that the high glyco-
lytic rate of tumors resulted from diminished or disturbed
respiration [24,25]. Recent studies suggest that mtDNA
mutations may contribute to the respiratory defects in
cancer [18]. Furthermore, studies of human tumors have
demonstrated an association between mtDNA somatic
mutations and tumor progression [26-28].
Few studies have evaluated mtDNA mutations in brain
cancer. Mitochondrial genome instability was found in
the hypervariable regions in the D-loop of human glio-
mas, meningiomas, schwannomas, gliomatosis cerebri,
glioblastomas, astrocytomas, and neurofibromas [29-33].
Other studies of the mitochondrial genome focused on
mtDNA copy number in brain tumors [34]. In the only
study examining the entire mitochondrial genome, Wong
et al. found that the majority of mtDNA somatic muta-
tions in medulloblastomas existed in regions of mononu-
cleotide repeats, rather than in genes encoding proteins
for the respiratory chain complexes [35]. A recent study in
mouse tumorigenic fibroblasts, suggest that nuclear muta-
tions rather than mtDNA mutations contribute to the
tumor phenotype [36]. It is not yet clear if mtDNA muta-
tions contribute to brain tumor progression.
In contrast to most tissues where mitochondrial morphol-
ogy and function is relatively homogeneous, mitochon-
dria in brain are heterogeneous and exist as non-synaptic
free mitochondria (FM), synaptic light mitochondria
(LM), and synaptic heavy mitochondria (HM) [37,38].
This morphological heterogeneity is thought to reflect the
metabolic heterogeneity of mitochondria within and
between the various neuronal and non-neuronal (glial)
cell populations [39]. Besides morphological heterogene-
ity, genetic heterogeneity in mtDNA has been reported in
normal human brain tissue [40]. In this study, we
sequenced the entire mitochondrial genome in a series of
chemically induced and spontaneous mouse brain
tumors that differ in metastasis, malignancy, and vascular-
ity. To our knowledge, no prior studies have compared the
sequence of the entire mitochondrial genome in brain
tumor cell lines with that of the syngeneic brain tissue.
Although we found several mutations, none of these were
considered pathogenic.
Methods
Mice and brain tumors
The inbred VM and C57BL/6J (B6) mouse strains were
obtained originally from Professor H Fraser, University of
Edinburgh, and from the Jackson Laboratory, Bar Harbor,
ME, respectively. All mice used in the study were propa-
gated in the animal care facility at Boston College using
animal husbandry conditions described previously [41].
All animal-use procedures were in accordance with the
NIH Guide for the Care and Use of Laboratory Animals
and were approved by the Institutional Animal Care
Committee.
The EPEN and CT-2A brain tumors were produced origi-
nally from implantation of 20-methylcholanthrene into
the brains of B6 mice as previously described [42,43]. The
EPEN tumor arose in the cerebral ventricle and was char-
acterized as an ependymoblastoma, whereas the CT-2A
tumor arose in the cerebral cortex and was characterized
as a poorly differentiated astrocytoma [42,44]. The CT-2A
tumor contains complex gangliosides, is highly ang-
iogenic in vivo, and grows in vitro as a fusiform monolayer
[42,45,46]. In contrast, the EPEN tumor expresses only
the simple ganglioside GM3, is less angiogenic in vivo, and
grows in vitro as cuboidal cell islands [41,42,46-49]. The
nonmetastatic (VM-NM) and the metastatic (VM-M)
tumors arose spontaneously in the brains of VM mice as
previously described for other VM brain tumors [50,51].
Tumor cell culture
Cultured cell lines were prepared from each tumor as we
previously described [52,53]. The number of passages for
CT-2A and EPEN cell lines were greater than 40, where as
VM-NM and VM-M were passaged 9 and 11 times, respec-
tively. The VM-M cell line maintained metastatic capacity
when implanted into VM mice. The tumor cells were
grown in Dulbecco's modified Eagle medium (DMEM)
supplemented with 10% heat-inactivated fetal bovine
serum (FBS) in a humidified atmosphere containing 95%
air and 5% CO2 at 37°C. Upon reaching confluency, the
cells were trypsinized and collected.
Mitochondrial isolation from brain tissue and cultured 
tumor cells
Mitochondria were isolated from VM and B6 cerebral cor-
tex according to previously described procedures [38,54].
Cerebral cortex mitochondria were separated into three
populations following ficoll gradient centrifugation.
These populations included non-synaptic free mitochon-
dria (FM), synaptic light mitochondria (LM), and synaptic
heavy mitochondria (HM). Mitochondria were isolated
from the tumor cell lines as a single enriched mitochon-
drial fraction as previously described [54,55]. Mitochon-
dria were isolated in duplicate independent samples from
each of the brain tumor cell lines for sequence
comparison.
Isolation and amplification of mouse mtDNA
mtDNA from cerebral cortex and cultured tumor cells was
isolated using the DNeasy Tissue Kit (QIAGEN, Valencia,BMC Cancer 2005, 5:102 http://www.biomedcentral.com/1471-2407/5/102
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CA, USA) and was amplified in 12 overlapping segments
covering the entire mitochondrial genome. PCR reactions
were performed in a volume of 50 µl using the Eppendorf
Master Taq system (Brinkmann Eppendorf, Westbury,
NY). Primers used for mtDNA amplification are given in
Table 1. PCR conditions for all primer pairs consisted of
an initial denaturation at 94°C for 120 s followed by 34
cycles of 94°C for 60 s, an annealing temperature of 57–
66°C for 35 s and 72°C for extension at 105 s. A final
extension was for 5 min. Optimal annealing temperatures
were determined by performing gradient PCR on each of
the primer sets.
mtDNA sequencing
Amplified regions of mtDNA were purified using a PCR
purification kit (MO BIO Laboratories, Solana Beach, CA)
and were then visualized by 1% agarose gel electrophore-
sis. DNA concentration was estimated using a Low DNA
Mass Ladder (Invitrogen, Carlsbad, CA) by gel electro-
phoresis. Approximately 25 fmol of the purified PCR
product was used in the sequencing reaction following
manufacturer's instructions for the CEQ DTCS kit (Beck-
man Coulter, Fullerton, CA). The amount of DNA used
varied depending on the size of the PCR fragment. The
primers in Table 1, together with 75 nested primers, were
used in the sequencing reactions to obtain double-
stranded sequence. Nested primer information can be
made available upon request to corresponding
investigators.
Sequencing reactions were performed at 96°C for 20 s,
50°C for 20 s, and 60°C for 240 s based on a 32 cycle reac-
tion. Sequencing products were ethanol precipitated in
cold 95% ethanol, washed twice with cold 70% ethanol,
dried for 20 minutes, and then re-dissolved in sample
loading solution provided by the manufacturer (Beckman
Coulter, Fullerton, CA). The mtDNA sequence alignments
were then compared to those from Mus Musculus [Gen-
Bank: V00711] [56] and from B6 mice [GenBank:
AY172335] [23].
Results
Analysis of mtDNA variation in B6 and VM mouse strains
Sequence analysis of the entire mitochondrial genome of
the VM and B6 mouse strains revealed a single nucleotide
base pair change at position 11780, found in both strains,
compared to the republished B6 sequence [23]. This
resulted in a T->A transversion, causing an amino acid
Table 1: Primers used for amplification of Mus Musculus mitochondrial genome
Primer pair mtDNA bp Forward primer Reverse primer
1 15309-00040 GGTCTTGTAAACCTGAAATGAAG GCATTTTCAGTGCTTTGCTTTG
2 16173-01436 CTGATCAATTCTAGTAGTTCC CAAGCTCGTTAGGCTTTTCAC
3 01314–02880 GAATTACAGCTAGAAACCCCG CGTATGGACCAACAATGTTAGG
4 02673–03873 GTTATTAGGGTGGCAGAGCCAG GCCCGATAGCTTAATTAGCTGAC
5 03731–05324 CTTTGATAGAGTAAATTATAGAGG TAAAATGGCTGAGTAAGCATTAG
6 05194–06593 GTCTTAGTAGAGATTTCTCTACAC GTTTACTCCTACGAATATGATGG
7 06477–07996 GGAGCAGTGTTTGCTATCATAGC TGATGGCTACAACGATTGGGAATC
8 07847–09438 GTCTCATCACAAACATTCCCAC CAGAATCTACTAATTGGAAGTCAG
9 09307–10806 GATTTGAAGCCGCAGCATGATAC GTCATAGGTGAACTCCATATAATGG
10 10647–12399 GCCCTCATCTTAATCCAAAACC CTGTAGCTGCGATTAATAGGC
11 12247–13788 CAATCCTCTATAACCGCATCG GTATTGGGGGTGATTATAGAG
12 13670–15498 CCAACATCATCAACCTCATAC GTACTAGCTTATATGCTTGGG
The nucleotide positions were based on Mus Musculus sequence from Bibb et al. 1981 [GenBank: V00711]
Table 2: Summary of mtDNA nucleotide variations in C57BL/6J and VM mouse strainsa
Mouse strain Nucleotide position Gene DNA change Amino acid change
C57BL/6J 11780 ND5 T->A Ile->Met
VM 11780 ND5 T->A Ile->Met
VM 9829 Arg tRNA InsA NAb
VM 9461 ND3 T->C Ile->Ile
Accession numbers for C57BL/6J and VM strains are DQ106412 and DQ106413, respectively
a Nucleotide variation compared to the republished C57BL/6J mtDNA sequence from Bayona-Bafaluy et al. 2003
b NA, not applicableBMC Cancer 2005, 5:102 http://www.biomedcentral.com/1471-2407/5/102
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change of an isoleucine to methionine in the ND5 gene
(Table 2). This transversion was found in all three brain
mitochondrial populations for both strains and existed in
all brain tumor cell lines corresponding to the host strain.
This was the only variation found between the B6 strain
sequence and the republished B6 sequence [23]. The VM
strain also had two additional nucleotide variations
compared to the B6 strain. The first variation was found in
the ND3 gene at position 9461. This caused a T->C transi-
tion, but resulted in no amino acid change. A second var-
iation existed in the poly-A tract of the Arg tRNA, where an
adenine was inserted at position 9829 (Table 2). The data
show that few mtDNA variations exist between the B6 and
VM inbred mouse strains.
mtDNA somatic mutations in mouse brain tumor cell lines 
compared to syngeneic host mtDNA sequence
Analysis of the EPEN brain tumor cell line revealed two
somatic mutations compared to the syngeneic B6 host
strain. One mutation involved an insertion of two
adenines in the Arg tRNA at position 9829 (Table 3). This
is not expected to alter Arg tRNA function because the
mutation occurred in a highly variable site in mouse
strains [23]. A second mutation involved a T->C transition
in the ND3 gene at position 9461, but did not change the
amino acid. Analysis of the CT-2A brain tumor cell line
revealed only a single mutation compared to the syn-
geneic B6 host strain. This involved an insertion of an ade-
nine in the OL at position 5182 (Table 3). This mutation
is also not likely to have functional consequence [23].
As in the chemically induced EPEN and CT-2A brain
tumor cell lines, only a few somatic mutations were found
in the VM brain tumor cell lines (VM-NM and VM-M)
compared to the syngeneic VM host (Table 3). Two
somatic mutations were found in the nonmetastatic VM-
NM cell line. The first mutation involved a deletion of an
adenine in the OL at position 5182. This is the same loca-
tion where the only variation was found in the CT-2A
tumor and is consistent with hypervariability in this
Table 3: Summary of mtDNA mutations in experimental mouse brain tumor cell linesa
Brain tumor 
cell line
Metastatic Host genetic 
background
Nucleotide 
position
Gene DNA change Stateb Amino acid 
change
EPEN - B6 9829 Arg tRNA InsAA Homo NAc
9461 ND3 T->C Homo Ile->Ile
CT-2A - B6 5182 OL InsA Homo NA
VM-NM - VM 5182 OL DelA Homo NA
15584 D-loop T->C Homo NA
VM-M + VM 2159 16srRNA A->G Hetero NA
a Tumor cell lines mtDNA sequences were compared to host strain brain mtDNA populations
b Homo, homoplasmy; hetero, heteroplasmy
c NA, not applicable
Heteroplasmy in the metastatic VM-M tumor cell line Figure 1
Heteroplasmy in the metastatic VM-M tumor cell line. Mito-
chondrial 16srRNA revealed a heteroplasmic mutation at 
position 2159 of an A to G transition. The three VM brain 
mitochondrial populations (LM, HM, and FM) displayed the 
same chromotagraph profile. The same level of heteroplasmy 
was observed in duplicate independent samples for the VM-
M cell line. Arrow indicates heteroplasmic nucleotide at posi-
tion 2159 compared to control.BMC Cancer 2005, 5:102 http://www.biomedcentral.com/1471-2407/5/102
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region [23]. The second mutation in this cell line involved
a T->C transition in the D-loop at position 15584. Neither
of these mutations have functional consequence.
A single mutation was found in the metastatic VM-M cell
line involving an A->G transition in the 16srRNA gene at
position 2159. In contrast to the other mtDNA mutations
found in either the B6 or the VM tumor cell lines, the A-
>G transition in the VM-M cell line was heteroplasmic
(Figure 1). This heteroplasmic mutation, however, was
not found in another independently derived cell line from
this metastatic tumor. Viewed together, these data indi-
cate that only a few mtDNA somatic mutations exist in the
chemically induced tumors in the B6 mice or in the spon-
taneous brain tumors in VM mice. Also, most of these
mutations were found in hypervariable regions and none
are considered pathogenic.
Discussion
The purpose of this study was to determine if mtDNA
mutations existed in chemically induced and spontane-
ous mouse brain tumors and whether such mutations
might provide insight on the development or progression
of these experimental brain tumors. To reduce the proba-
bility of detecting spurious pathogenic mutations, we
compared the mtDNA sequence of each brain tumor cell
line with that of normal mtDNA from the syngeneic
mouse host strains. Furthermore, to avoid the coamplifi-
cation of mitochondrial pseudogenes that exist in nuclear
DNA, we amplified only large mtDNA fragments (1–1.8
kb in length) in isolated mitochondria [18,57,58].
Because the solid tumors become infiltrated with host
stromal cells containing wildtype mitochondria [59], we
used cultured tumor cell lines for these studies instead of
whole tumor tissue. Hence, our experimental design will
detect any mtDNA mutation that could alter mitochon-
drial function.
Several mtDNA mutations were found in the mouse brain
tumor cell lines, but most of these were located in hyper-
variable mononucleotide hotspot regions, such as in the
OL and in the Arg tRNA for mouse mtDNA. Moreover,
none of these mutations were considered pathogenic
since they did not change amino acid sequence and there-
fore could not alter gene function. Tumor cells in each line
were selected from original tumors that may have con-
tained multiple transformed cell types. The lines therefore
represent only those cells with the most aggressive malig-
nant growth in vitro and in vivo. The absence of pathogenic
mutations in these tumor cells, further suggests that
mtDNA mutations do not likely contribute to the initia-
tion or the progression of these diverse mouse brain
tumors.
Most tumors including brain tumors express abnormali-
ties in the number and function of their mitochondria
[60,61]. Warburg originally emphasized that the high gly-
colytic rate of tumors results from diminished or dis-
turbed respiration [24,25]. Later studies in a variety of
neural and non-neural tumor systems showed that these
respiratory disturbances could involve abnormalities in
TCA cycle components, alterations in electron transport,
and deficiencies in oxidative phosphorylation [62-66].
Recent studies also suggest that mtDNA mutations may
contribute to the respiratory defects in cancer [18]. Our
findings indicate that diminished respiration and the
glycolytic dependence of the chemically induced CT-2A
and EPEN brain tumors or the two spontaneous VM brain
Table 4: mtDNA alterations in human brain tumors compared to matched tissue controls
Type of tumor Number of tumors Number of tumors 
with mtDNA 
somatic mutationsa
Number of somatic 
mutations causing 
amino acid 
substitutionsc
Region of mutation Reference
Neurofibroma 37 23/37 NAd D-loop Kurtz et al. 2004
Glioma 53 20/53 NA HVRII Vega et al. 2004
Meningioma 11 5/11 NA
Schwannoma 5 1/5 NA
Medulloblastoma 15 6/15 2/18 D-loop, Asp tRNA, 
COXI, CoxII, Thr 
tRNA, ND4
Wong et al. 2003
Gliomatosis cerebri 6 2/6 NA HVRII Kirches et al. 2003
Glioma 55 12/55 NA HVRII, D-loop Kirches et al. 2001
Astrocytoma 12 11/12b NA HVRII Kirches et al. 1999
a Number of tumors with mutations/number of tumors
b 2 of the 12 astrocytomas were compared to adjacent brain, the remaining 10 were aligned to Anderson et al. 1981 for mutation analysis
c Number of mutations causing amino acid substitutions/total number of mutations found in all tumors
d NA, not applicable because in hypervariable region of the D-loop (HVR)BMC Cancer 2005, 5:102 http://www.biomedcentral.com/1471-2407/5/102
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tumors studied here do not result from somatic mutations
in their mtDNA.
In contrast to previous reports of genetic heterogeneity in
normal human brain mtDNA, [40,67] we found no evi-
dence for genetic heterogeneity in mtDNA isolated from
synaptic and nonsynaptic mitochondria in the C57BL/6J
and VM mouse strains by direct sequencing. On the other
hand, our findings that most mtDNA changes in the
mouse brain tumors were in hypervariable regions of
mononucleotide repeats are in general agreement with
previous studies in human brain tumors (Table 4). We
detected a single heteroplasmic mutation in the 16srRNA
gene of the VM-M metastatic cell line, which was deter-
mined by sequence analysis [68]. Since this heteroplasmic
mutation was not detected in another independently
derived cell line from this tumor, it is unlikely that the
mutation is associated with either tumorigenesis or metas-
tasis. The EPEN cell line contained a nucleotide variation
compared to the B6 genotype at position 9461 in the ND3
gene. This nucleotide variation in the EPEN cell line also
was found in the VM-NM and VM-M cell lines. This poly-
morphism could be due to a base pair wobble at that loca-
tion or could result from a nucleotide variation in the
original C57BL/6J mouse from which the EPEN tumor
arose [44].
The four mouse brain tumor cell lines we examined repre-
sent both spontaneous and chemically induced tumors
that differ in cell origin, biochemical composition, and
angiogenesis. The selection of the cell lines provides a
comparison for defining the contribution that mtDNA
might play in carcinogenesis. Although we did not find
any mtDNA pathogenic mutations in these brain tumors,
we do not rule out the possibility that such mutations
might occur in other spontaneous mouse brain tumors or
in mouse brain tumors induced with other chemical car-
cinogens. Our findings suggest that mtDNA mutations do
not likely contribute to the development or progression of
CT-2A or EPEN chemically induced tumors or the meta-
static and nonmetastatic spontaneous VM brain tumors.
With the exception of a single variation at nucleotide
11780 in the ND5 gene, our whole mitochondrial
genome sequence for the B6 strain was in complete agree-
ment with the recently republished sequence for this
mouse strain [23]. This single nucleotide difference
involved a T->A transversion that changed isoleucine to
methionine. This difference was also found in the VM
mouse strain as well as in all examined mouse brain
tumor cell lines. It is not yet clear if this variation
represents an error in the republished B6 mtDNA
sequence or a population genetic variation among B6
mouse strains. Brain mitochondria were fractionated into
different populations for genotyping to confirm that there
was no mtDNA heterogeneity in hypervariable regions
that might be associated with metabolic heterogeneity.
Sequencing of all three brain populations also served as
an internal control for the genotype of the mouse strains.
In summary, our results show that the mitochondrial
genome of these mouse brain tumor cell lines contain
mutations in regions of mononucleotide repeats. These
mtDNA mutations in the mouse brain tumors are similar
to those found previously in hypervariable regions of the
D-loop in human brain tumors. However, none of the
mouse mutations were pathogenic suggesting that
mtDNA changes do not contribute to the carcinogenic
progression of these chemically induced and spontaneous
mouse brain tumors.
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